Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Achillion Is Burnt Toast

At this point, I'll be quite happy to never hear or read the word "Achillion" again, as my former positive calls on Achillion Pharmaceuticals (NASDAQ:ACHN) just keep looking worse and worse. With the company's post-Friday close clinical update, it's very difficult to argue that there's enough value left in this name to bother with it even further. I have no doubt that there will be a "never say die" contingent that wants to stick with this name, and I suppose I can't completely rule out the possibility that the next drug combo will work, but the combination of weak data, questionable reporting of that data, and the emerging competitive landscape just makes it too hard to look at...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details